Ramakrishna Nirogi

1 presentation

• T48. ROPANICANT (SUVN-911), AN α4β2 NACHR ANTAGONIST: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, EVALUATING THE EFFICACY AND SAFETY OF ROPANICANT IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)

  2026 ASCP Annual Meeting